Compare Merck & Co., Inc. (MRK) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Verizon Communications Inc — how do they compare? Merck & Co., Inc. trades at $145.6 (market cap $351.28B), while Verizon Communications Inc trades at $41.65 (market cap $192.57B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and Verizon Communications Inc pays the higher dividend (6.11%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Verizon Communications Inc for 109 Days on average.
| MRK | VZ | |
|---|---|---|
Market Cap | $351.28B | $192.57B |
Volume | 7,969,665 | 20,940,094 |
Sector | Health | Media |
52-Week High | $156.43 | $51.45 |
52-Week Low | $82.49 | $38.40 |
Typical Hold Time | 98 Days | 109 Days |
Enterprise Value | $398.04B | $379.28B |
Dividend Yield | 2.39% | 6.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01 billion in 2025, and net income reached $18.25 billion. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, with institutional investors increasing stakes.
The outlook for Merck is supported by analyst consensus with a $158.78 price target and 68% buy ratings, but risks include high valuation multiples like a P/E of 113.9 and competitive pressures in the pharma sector. The stock's investment appeal hinges on pipeline execution and integration of acquisitions amid a challenging technical backdrop.
Verizon (VZ) trades at $46.35, up 1.27% today, with a bearish technical signal despite recent earnings beats. The stock shows stable revenue around $138B annually with strong cash flow generation of $37.1B from operations in 2025. Valuation metrics appear reasonable with P/E of 12.07 and EV/EBITDA of 7.9, while the company maintains a solid dividend yield supported by consistent cash flows.
Outlook remains stable with moderate growth prospects amid competitive telecom landscape. Investment appeal centers on dividend reliability and defensive positioning, though technical weakness and modest revenue growth present near-term challenges. Risks include intense competition and capital expenditure requirements for network expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
